ZURICH (Reuters) – Johnson & Johnson’s
The sale corresponds to approximately 8.3% of Swiss drugmaker Idorsia’s outstanding ordinary share capital. Goldman Sachs
(Reporting by Brenna Hughes Neghaiwi; Editing by Michael Shields)
ZURICH (Reuters) – Johnson & Johnson’s
The sale corresponds to approximately 8.3% of Swiss drugmaker Idorsia’s outstanding ordinary share capital. Goldman Sachs
(Reporting by Brenna Hughes Neghaiwi; Editing by Michael Shields)
